Source:http://linkedlifedata.com/resource/pubmed/id/10503119
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1999-10-26
|
pubmed:abstractText |
1. Among 5,776 transplants reported to the UNOS Scientific Renal Transplant Registry with flow cytometry crossmatch (FCXM) results, 13% had a positive FCXM. The majority (8.8%) had B-cell only reactivity and the remaining 4.2% had T-cell reactivity. 2. Retransplanted patients, females and sensitized patients were more likely to have been FCXM positive than primary transplants, males, or unsensitized patients. 3. A positive FCXM was associated with less than optimal function as evidenced by an increased need for posttransplant dialysis, more grafts that never functioned, longer hospital stays and a higher incidence of rejection. 4. The impact of antibodies detected by FCXM on graft survival was strongest among retransplanted patients (60% 3-year graft survival with a positive FCXM vs 79% with a negative FCXM, p = 0.003), although significant differences were also noted in primary transplants (76% 3-year graft survival with a positive FCXM vs 81% with a negative FCXM, p < 0.001). Class I reactivity generally had a greater impact on survival, although class II antibodies had a deleterious effect as well. 5. Primary transplants across a T+B+ FCXM (n = 187) had a 76% 3-year graft survival rate compared with 74% for 509 T-B+ transplants. Both were significantly lower than the 81% 3-year graft survival rate for 5,017 T-B- FCXM transplants. 6. Retransplants across a T+B+ FCXM (n = 48) had a 60% 3-year regraft survival rate compared with 73% for 118 T-B+ regrafts and 79% when the FCXM was negative when tested against both targets (T-B-, n = 698). 7. Although there is room for improvement in the technique, the FCXM continues to be effective in identifying kidney transplants at risk of early graft failure and of rejection.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0890-9016
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
413-9
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10503119-B-Lymphocytes,
pubmed-meshheading:10503119-Female,
pubmed-meshheading:10503119-Flow Cytometry,
pubmed-meshheading:10503119-Graft Survival,
pubmed-meshheading:10503119-Histocompatibility Testing,
pubmed-meshheading:10503119-Humans,
pubmed-meshheading:10503119-Kidney Transplantation,
pubmed-meshheading:10503119-Male,
pubmed-meshheading:10503119-Postoperative Complications,
pubmed-meshheading:10503119-Registries,
pubmed-meshheading:10503119-Reoperation,
pubmed-meshheading:10503119-Retrospective Studies,
pubmed-meshheading:10503119-Risk Factors,
pubmed-meshheading:10503119-T-Lymphocytes,
pubmed-meshheading:10503119-Tissue and Organ Procurement,
pubmed-meshheading:10503119-Treatment Outcome,
pubmed-meshheading:10503119-United States
|
pubmed:year |
1998
|
pubmed:articleTitle |
Flow cytometry crossmatching (FCXM) in the UNOS Kidney Transplant Registry.
|
pubmed:affiliation |
Cleveland Clinic Foundation, Transplant Center, Ohio, USA.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|